Glucagon Function and Key Product Attributes in Peptide Therapeutics
Abstract: Glucagon, a 29-amino acid peptide hormone, is critical in glucose homeostasis and emerging as a key therapeutic for hypoglycemia and metabolic disorders. Current peptide therapeutics market trends show a CAGR exceeding 8%, driven by innovations in stability and delivery. Comparative analysis of brands (e.g., GlucaGen vs. Baqsimi) highlights trade-offs between injection (high bioavailability, cold-chain logistics) and nasal delivery (rapid onset, lower stability). Key product attributes include purity (>98%), aggregation profile, and regulatory certifications (FDA, EMA). Selection criteria prioritize lyophilized formulations for extended shelf-life and validated manufacturing facilities (GMP). Industry data indicates a shift toward dual-action glucagon analogs, expanding applications beyond rescue therapy.